Synchronous and Non-Synchronous Semelparity in Sibling Species of Pulmonates

Diverse life histories have been documented in terrestrial pulmonates, which inhabit different regions in climate. Life history traits are often phenotypically plastic and vary depending on the environment. Thus, surveys using designs that control for the confounding effects of environment are needed to evaluate the evolutionary differences between populations of closely related species in the wild. We examined the life histories of sibling species of terrestrial pulmonate within two regions of similar climates. Bradybaena pellucida (BP) is endemic to Japanese islands, and has recently been expanding its distribution northeastward, whereas B. similaris (BS) has been introduced by humans into temperate and tropical regions worldwide. We found that these species exhibit discrete differences in population dynamics and life cycle, despite their close relatedness. The annual life cycle of BP is synchronized among individuals in a population. Thus, BP is univoltine with discontinuous generation. In contrast, BS individuals do not synchronize their growth or reproduction, and thus exhibit overlapping generations. Our results indicate that synchronized and non-synchronized population dynamics diverge relatively rapidly in semelparous pulmonates. This type of difference has not been documented in pulmonate life history, and may have been overlooked because only a few studies have explicitly compared life cycles of closely related species within the same climate. Our results provide a basis for further studies of life history evolution in pulmonates.ArticleZOOLOGICAL SCIENCE. 32(4):372-377 (2015)journal articl

Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force

\ua9 2024 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.Background: Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD. Methods: We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration\u27s Risk of Bias tool for Randomized trials. Results: Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias. Conclusions: Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers